Results 131 to 140 of about 30,510 (258)

Osteoarthritis: An Immuno‐Inflammatory Disease‐Mechanisms of Immune Cell Dysregulation and Potential Therapeutic Strategies

Med Research, EarlyView.
This review summarizes the immuno‐inflammatory mechanisms driving the pathogenesis of osteoarthritis (OA), extending beyond the traditional view of OA as a purely degenerative disease to incorporate immune cell infiltration, inflammatory factor release, and the formation of a chronic low‐grade inflammatory microenvironment.
Qingqiang Lei, Xiaoxian Lou, Xu Su, Shubao Liu, Yanli Tong, Jie Chen, Xuerui Chen, Wenjun Mao, Hui Yu, Liangbin Lin   +9 more
wiley   +1 more source

WDEIA case series: Do unique clinical presentations suggest mechanistic differences? [PDF]

J Allergy Clin Immunol Glob
Sridhara S, Diab O.
europepmc   +1 more source

Toxicity Differences Between Microplastics and Nanoplastics in Organs: From Molecular Mechanisms to Potential Therapeutic Strategies

Med Research, EarlyView.
This review systematically compares the size‐dependent toxicity of microplastics and nanoplastics in the intestine, liver, kidney, lung, and brain. Particle size determines bioavailability, barrier penetration, and injury mechanisms. Because of their small size and high surface reactivity, NPs readily cross the intestinal epithelium and blood–brain ...
Yixian Cheng, Junjie Chen, Rui Fu, Jiawei Zhang, Jianguang Jia, Wei Wang, Zheng Zhang, Peng Zhang, Haosong Chen, Huake Cao, Gang Li, Weiwei Sheng, Ting Li, Bo Chen, Guodong Cao   +14 more
wiley   +1 more source

Biomarkers of equine asthma: A review of the current literature. [PDF]

Vet Res Commun
Długopolska D, Siwińska N, Noszczyk-Nowak A, Niedźwiedź A, Żak-Bochenek A.   +4 more
europepmc   +1 more source

Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression

Medicinal Research Reviews, EarlyView.
ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu, Saurabh Upadhyay, Moustafa T. Gabr   +2 more
wiley   +1 more source

Rehabilitation effects of high-intensity interval training on asthma: a systematic review and meta-analysis of randomized controlled trials. [PDF]

J Thorac Dis
Tang G, Cheng Y, Zeng K.
europepmc   +1 more source

How Can We Improve the Assessment and Indifferent Outcomes From Pelvic Organ Prolapse Management From Conservative and Surgical Therapies? ICI‐RS 2025

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Pelvic organ prolapse is a common condition and many women seek surgical treatment for prolapse symptoms. However, recurrence of prolapse after surgical treatment is common. A think tank was held at ICI‐RS 2025 to discuss how the assessment and indifferent results from conservative and surgical management can be improved.
Rohna Kearney, Adrian Wagg, Wendy Bower, Chris Chapple, Vik Khullar, Dudley Robinson, Annika Taithongchai, Philip Toozs Hobson, Alan Wein, Paul Abrams   +9 more
wiley   +1 more source

Pathological changes and therapeutic strategies for sarcopenia. [PDF]

EFORT Open Rev
Yang K, Peng S, Zhang C, Guo L, Liang D, Tao L.   +5 more
europepmc   +1 more source

Real‐World Safety and Effectiveness of Glatiramer Acetate in Patients With Multiple Sclerosis: Final Results of Post‐Marketing Surveillance in Japan

Neurology and Clinical Neuroscience, EarlyView.
ABSTRACT Background Glatiramer acetate is an injectable disease‐modifying therapy indicated for multiple sclerosis (MS). Aim To evaluate the real‐world safety and effectiveness of glatiramer acetate for MS in Japan. Methods A prospective, multicenter, observational, all‐case post‐marketing survey was conducted in Japan between November 2015 and March ...
Masaaki Niino, Eriko Hayashi, Mai Itani, Jun‐ichi Kira   +3 more
wiley   +1 more source

Real-life lessons on omalizumab and food allergy: The potential for unexplored outcomes. [PDF]

World Allergy Organ J
Lo Scalzo L, Galletta F, Cafarotti A, Nurmatov U, Klimek L, Fiocchi A, Arasi S.   +6 more
europepmc   +1 more source